

Carospir® (spironolactone) - First-time generic

- On November 2, 2023, <u>Amneal launched</u> an <u>AB-rated</u> generic version of CMP Pharma's <u>Carospir</u> (spironolactone) oral suspension.
 - In addition, Padagis launched an authorized brand alternative of Carospir.
- Carospir is approved:
 - For treatment of New York Heart Association Class III IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure
 - As an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents, and
 - For the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction.
- Spironolactone is also available generically as a <u>tablet</u>, and a combination <u>tablet with</u> <u>hydrochlorothiazide</u>.
 - Spironolactone is indicated for the treatment of congestive heart failure (CHF), hypertension, edema associated with hepatic cirrhosis or nephrotic syndrome, and primary hyperaldosteronism.
 - Spironolactone and hydrochlorothiazide are indicated for edamatous conditions associated with CHF, cirrhosis of the liver accompanied by edema and/or ascites, nephrotic syndrome, and essential hypertension.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.